LY2228820 (Dimesylate), 1mg

STEMCELL Technologies offers this small molecule as a trisubstituted imidazole derivative that acts as a potent inhibitor of the α- and β-isoforms of p38 MAP kinase (MAPK), with demonstrated anti-inflammatory and anti-neoplastic activities. The compound is also referred to as Ralimetinib Mesylate and LSN2322600, and is supplied as the dimesylate salt.

The chemical name is 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine, dimethanesulfonate, with CAS number 862507-23-1, a molecular formula of C₂₄H₂₉FN₆ • 2CH₃SO₃H, and a molecular weight of 612.7 g/mol. The product is provided as a crystalline solid with a purity of ≥ 98%. It is soluble in water (≤ 200 mM), DMSO (≤ 55 mM), and absolute ethanol (≤ 4.8 mM).

The product is stable at -20°C as supplied, should be protected from prolonged exposure to light, and stored with a desiccant for long-term storage. Published applications include the maintenance and self-renewal of hematopoietic stem cells when combined with other small molecule inhibitors, and use in cancer research, where inhibition of p38 MAPK shows potent and selective inhibition of tumor growth in animal models of human cancers. For research use only; not intended for human or animal diagnostic or therapeutic uses.